Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.
Intel has spent the past year adding tools for gathering and analyzing data, notably by taking a stake in Cloudera and buying Basis. And the strategy now has a major test case, with the Michael J. Fox Foundation teaming up with Intel to remotely monitor people with Parkinson's disease.
A Wall Street Journal feature this week on researchers' long-standing concerns about the consequences of patients talking about clinical trials online digs into how biopharma companies are tapping technology to counter concerns about unblinding and manipulating inclusion/exclusion criteria.
While virtual biotechs and the service providers that support them have been around for years, Transcriptic and rival West Coast startups think they can improve the model through automation. And having raised cash from Google's venture unit and struck deals with some elite academic centers, Transcriptic is now rolling out the next phase of its plan.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
If the Michigan-based company--which describes itself as "Match.com for clinical trials"--achieves its goal, it will have doubled the number of top-5 companies on its books.
While PhRMA, EFPIA and other trade groups have established positions on trial data transparency, Big Pharma consortium TransCelerate BioPharma has been on the periphery of the public debate. Behind the scenes though it has been looking into the best way to redact information--and has shared its thoughts on the topic with the European Medicines Agency (EMA).
The controversy surrounding the European Medicines Agency's trial data transparency draft terms put this week's management board meeting in the spotlight, with campaigners hoping the regulator would rethink its policy. And to an extent, the EMA did, but the compromise it proposed is unlikely to fully satisfy either side of the debate.
Cambridge Cognition has introduced two iPad-based products for use in clinical trials.
The potential cost savings generated by risk-based monitoring of clinical trials has led some to tip it as a way to significantly streamline pharma's flabby studies. And that potential has lured tech providers, with Medidata and Parexel both advancing their claims on the market this week.